TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29481979

Group type: EXPERIMENTAL
Intervention: 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 256

Group type: COMPARATOR
Intervention: 0, 6, 12, or 18 sessions of spinal manipulative therapy (SMT)
Number of subjects: 256
Study: 26843373

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the supplementary motor area
Number of subjects: 50

Group type: COMPARATOR
Intervention: TAU (treated as usual with antipsychotics)
Number of subjects: 50
Study: 24588789

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: No glyceryl trinitrate
Number of subjects: 0
Study: 22628591

Group type: EXPERIMENTAL
Intervention: Short anatomical cementless stem
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional cementless stem
Number of subjects: 70
Study: 20156981

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18754763

Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 16000606

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy (300-400 mg/m2) for 3-4 cycles
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 1867
Study: 12873248

Group type: EXPERIMENTAL
Intervention: 60 mg/day dexamphetamine (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study: 10232112

Group type: EXPERIMENTAL
Intervention: CNS sutured group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical staff sutured group
Number of subjects: 0
Study: 8730431

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2065826

Group type: COMPARATOR
Intervention: Antituberculous drugs only
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Intrathecal hyaluronidase
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide and furosemide in addition to antituberculous treatment
Number of subjects: 81
Study: 6406460

Group type: EXPERIMENTAL
Intervention: Bupropion (12.5 mg to 100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31593253

Group type: EXPERIMENTAL
Intervention: Transitional care support and long-term self-management
Number of subjects: 0
Study: 29456043

Group type: COMPARATOR
Intervention: Colistin monotherapy (9-million unit loading dose, followed by 4·5 million units twice per day)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (2-g prolonged infusion three times per day)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem
Number of subjects: 406

Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 406
Study: 27068631

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg 12 hours before and 400 mg 2 hours before coronary angiography)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (0.9% saline infusion)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 24560970

Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (SWL)
Number of subjects: 70
Study: 22794217

Group type: EXPERIMENTAL
Intervention: 2 mg/mL berberine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/mL berberine plus 1% CHX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% CHX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 0
Study: 19274607

Group type: EXPERIMENTAL
Intervention: Videotaped patient consultation with actors portraying patients with depression symptoms.
Number of subjects: 128
Study: 17916078

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched subjects)
Number of subjects: 70
Study: 16271688

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Concentric strengthening with stretching
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening with stretching
Number of subjects: 94
Study: 11902153

Group type: EXPERIMENTAL
Intervention: Studying associates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presenting prototypes in predictive or incongruous contexts
Number of subjects: 0
Study: 10322043

Group type: EXPERIMENTAL
Intervention: Unilateral median nerve stimulation with brief current pulses at 2 Hz for 800-1,500 trials; 15% of pulses omitted at random intervals.
Number of subjects: 0
Study: 9086318

Group type: EXPERIMENTAL
Intervention: Exercise training program (5 days/week for 15 weeks, including weight training 2 days/week and aerobic training 3 days/week)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (team sports program)
Number of subjects: 17
Study: 2020612

Group type: EXPERIMENTAL
Intervention: Butorphanol 1.0 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Butorphanol 3.0 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg and 3.0 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 and 3.0 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Butorphanol (all doses)
Number of subjects: 52
Study: 7195004

Group type: EXPERIMENTAL
Intervention: Lactose elimination diet
Number of subjects: 103

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lactose malabsorbers
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lactose absorbers
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Recurrent abdominal pain group
Number of subjects: 103
Study: 31306506

Group type: EXPERIMENTAL
Intervention: 1% magnesium sulphate added to 1.8% lidocaine with 1:88,000 epinephrine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 1.8% lidocaine with 1:88,000 epinephrine
Number of subjects: 68
Study: 29680319

Group type: EXPERIMENTAL
Intervention: 16 sessions of cognitive and/or behavioral intervention tailored to symptom severity across 12 months along with routine medical care
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 139
Study: 26387689

Group type: EXPERIMENTAL
Intervention: Goal-setting
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 8

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 8
Study: 25012240

Group type: EXPERIMENTAL
Intervention: Fasting triglycerides >150 mg/dl
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Area under the curve >1120 mg/dl/5 hr
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Upper tertile of fasting triglycerides
Number of subjects: 514

Group type: COMPARATOR
Intervention: Postprandial triglycerides
Number of subjects: 514

Group type: COMPARATOR
Intervention: Total cholesterol, LDL- and HDL-cholesterol concentrations
Number of subjects: 514
Study: 22855822

Group type: EXPERIMENTAL
Intervention: Encoding brain scores reflecting hippocampal functioning
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: General cognitive-control network scores
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Bilateral hippocampus activity
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Brain structure analyses
Number of subjects: 292
Study: 20520283

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg BID
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg BID
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg BID
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 18516753

Group type: EXPERIMENTAL
Intervention: Interferential current therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biofeedback pelvic floor exercises
Number of subjects: 40
Study: 15960566

Group type: COMPARATOR
Intervention: No SUD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Current SUD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Past SUD
Number of subjects: 1000
Study: 12424330

Group type: EXPERIMENTAL
Intervention: Tomato sauce supplementation (30 mg of lycopene/day) for 3 weeks
Number of subjects: 32
Study: 10622345

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU), 20 mg QD for 11 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study: 7860944

Group type: EXPERIMENTAL
Intervention: Partner-supported, incentive-based educational program including special incentives (prizes) for women and their partners to participate in a breast‐feeding class and an educational series on childbirth.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual breast‐feeding education (control group).
Number of subjects: 68
Study: 2019135

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucose and conventional amino acid solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucose and branch-chain amino acid enriched solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amino acid infusions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Leg VO2
Number of subjects: 19
Study: 7046898

Group type: COMPARATOR
Intervention: Chlorpromazine (300 mg to 2100 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pimozide (10 to 70 mg)
Number of subjects: 20
Study: 31841599

Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 30169811

Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Successful aging education control group
Number of subjects: 1635
Study: 28558673

Group type: EXPERIMENTAL
Intervention: Geo-specific poster
Number of subjects: 752

Group type: COMPARATOR
Intervention: Standard poster
Number of subjects: 752
Study: 25142867

Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz, 10 s, 10 trains with 80% intensity)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 34
Study: 23252480

Group type: EXPERIMENTAL
Intervention: FibReORS (Apically Positioned Flap with Fibre Retention Osseous Resective Surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ORS (Osseous Resective Surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both FibReORS and ORS
Number of subjects: 30
Study: 21211560

Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (Geriforte tablets)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18753466

Group type: EXPERIMENTAL
Intervention: Baseline 8-Isoprostane (8-IsoP) levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FENO levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 46
Study: 17114906

Group type: EXPERIMENTAL
Intervention: H2RB and/or PPI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PA with autoimmune thyroid disease
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High baseline gastrin levels
Number of subjects: 62
Study: 15565751

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11353965

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum cholecystectomy (PP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Laparoscopic gasless cholecystectomy (AWL)
Number of subjects: 15
Study: 9056163

Group type: EXPERIMENTAL
Intervention: Calcidiol (32,000 IU/weekly)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcitonin (100 UI/d, nasal route)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg p.o./d/2 weeks/3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcitonin and Etidronate
Number of subjects: 40
Study: 8585422

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate 120 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate (all doses)
Number of subjects: 21
Study: 2486655

Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms in 2 ml added to 12 ml of 0.25% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 80 micrograms in 8 ml added to 12 ml of 0.25% bupivacaine
Number of subjects: 60
Study: 1125699

Group type: EXPERIMENTAL
Intervention: Selective vagotomy and pyloroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Truncal vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective vagotomy
Number of subjects: 0
Study: 31300879

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Professional esthetic perception
Number of subjects: 12
Study: 31604478

Group type: EXPERIMENTAL
Intervention: Strengthening exercises for the trunk, hip, and knee muscles
Number of subjects: 90

Group type: COMPARATOR
Intervention: Strengthening exercises for the trunk, hip, and knee muscles with neuromuscular training exercises starting from the fourth week
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neuromuscular training exercises
Number of subjects: 90
Study: 25567289

Group type: EXPERIMENTAL
Intervention: Practical approach to lung health strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informal healthcare provider interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23078156

Group type: EXPERIMENTAL
Intervention: HBD3 peptide gel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (CH)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CHX)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mismatched peptide gel (MP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study: 21628598

Group type: EXPERIMENTAL
Intervention: RI-affirmation writing task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrimination scenario
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondiscrimination scenario
Number of subjects: 0
Study: 18458163

Group type: EXPERIMENTAL
Intervention: Salt tablets (200 mmol/d of sodium)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16540841

Group type: EXPERIMENTAL
Intervention: Resistance exercise (90-min bout, 80% of 12-repetition maximum)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 10
Study: 14507828

Group type: EXPERIMENTAL
Intervention: Oxytocin 0.75 IU
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 49
Study: 11191537

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day, increased to 20 mg/day if weight regain occurred)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 605
Study: 8773907

Group type: EXPERIMENTAL
Intervention: Anti-core ELISA
Number of subjects: 718
Study: 1519781

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (4 micrograms/kg, in 20 ml normal saline) before surgical incision, followed by epidural normal saline (20 ml) infused 15 min after incision.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural normal saline (20 ml) before surgical incision, followed by epidural fentanyl (4 micrograms/kg, in 20 ml normal saline) infused 15 min after incision.
Number of subjects: 30
Study: 6337610

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 29576001

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 30244705

Group type: EXPERIMENTAL
Intervention: Intermediate-high risk OSA group (STOP-BANG score ≥ 3)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Low-risk OSA group (STOP-BANG score < 3)
Number of subjects: 128
Study: 26367217

Group type: COMPARATOR
Intervention: melphalan 200 mg/m² (mel200)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: melphalan 280 mg/m² (mel280)
Number of subjects: 131

Group type: COMPARATOR
Intervention: mel200
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: mel280
Number of subjects: 131
Study: 24375768

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 1000 mg once-daily
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 800 mg once-daily
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 600 mg once-daily
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) with ribavirin (RBV)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 24 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 36 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Response-guided treatment
Number of subjects: 249
Study: 21664286

Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 0

Group type: COMPARATOR
Intervention: BM
Number of subjects: 0
Study: 19403950

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with casein (CAS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with whey (WP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein beverages with casein and whey blend (CAS-WP)
Number of subjects: 10
Study: 17489483

Group type: EXPERIMENTAL
Intervention: Grandio (Voco)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filtek Supreme (3M ESPE)
Number of subjects: 30
Study: 15673037

Group type: EXPERIMENTAL
Intervention: Modest training (20 trials) with visual and proprioceptive information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive training (720 trials) with visual and proprioceptive information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proprioceptive information only
Number of subjects: 0
Study: 12401850

Group type: EXPERIMENTAL
Intervention: Oral theophylline 200 mg b.d. 24 h before and for 48 h after CAG
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine CAG (Control group)
Number of subjects: 70
Study: 9832182

Group type: EXPERIMENTAL
Intervention: cyclosporine (20 mg/kg body weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: vehicle (olive oil)
Number of subjects: 16
Study: 9466506

Group type: EXPERIMENTAL
Intervention: Intratracheal pulmonary ventilation (ITPV)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional ventilation (Control)
Number of subjects: 5
Study: 2792172

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of frusemide with plasma volume expansion (albumin infusion)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intravenous bolus of frusemide without plasma volume expansion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Infusion of dextran
Number of subjects: 5
Study: 88754

Group type: EXPERIMENTAL
Intervention: Chemotherapy (methotrexate 400 mg followed by citrovorum factor 100 mg + bleomycin 60 mg/week for the first 15 weeks)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Immunotherapy (weekly C. parvum injections for 2 years)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All treatments (Chemotherapy, Immunotherapy, No treatment)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Patients who previously received radiotherapy
Number of subjects: 95
Study: 27872389

Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention (n=24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition based on the question‐behaviour effect (n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implementation intentions and question‐behaviour effect
Number of subjects: 50
Study: 28864651

Group type: EXPERIMENTAL
Intervention: Knee effusion-synovitis
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Baseline BML, cartilage defect, JSN, and osteophyte scores
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Baseline cartilage defects and JSN
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Change in effusion-synovitis volume
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Effusion-synovitis
Number of subjects: 413
Study: 25110303

Group type: EXPERIMENTAL
Intervention: Text message intervention (approximately 3 messages per week)
Number of subjects: 87
Study: 23513200

Group type: EXPERIMENTAL
Intervention: 100% deproteinised bovine bone matrix (DBBM) grafts
Number of subjects: 40

Group type: COMPARATOR
Intervention: 100% autogenous bone (AB) grafts
Number of subjects: 40
Study: 21471550

Group type: EXPERIMENTAL
Intervention: Tramadol/paracetamol (37.5+325 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Paracetamol monotherapy (1000 mg)
Number of subjects: 114
Study: 19258386

Group type: EXPERIMENTAL
Intervention: Keto acid-supplemented low-protein diet (sLP: 0.6-0.8 g/kg IBW/day with 0.12 g/kg IBW/day of keto acids)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-protein diet (LP: 0.6-0.8 g/kg IBW/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-protein diet (HP: 1.0-1.2 g/kg IBW/day)
Number of subjects: 60